617 related articles for article (PubMed ID: 30806814)
41. Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors.
Kreamer K; Riordan D
Clin J Oncol Nurs; 2015 Dec; 19(6):734-42. PubMed ID: 26583637
[TBL] [Abstract][Full Text] [Related]
42. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
43. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
44. Personalized therapy for lung cancer: striking a moving target.
Pakkala S; Ramalingam SS
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089719
[TBL] [Abstract][Full Text] [Related]
45. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
Chin LP; Soo RA; Soong R; Ou SH
J Thorac Oncol; 2012 Nov; 7(11):1625-30. PubMed ID: 23070242
[TBL] [Abstract][Full Text] [Related]
46. Novel therapeutic targets in non-small cell lung cancer.
Alamgeer M; Ganju V; Watkins DN
Curr Opin Pharmacol; 2013 Jun; 13(3):394-401. PubMed ID: 23608109
[TBL] [Abstract][Full Text] [Related]
47. [Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
Álvarez-Fernández C; Esteban-González E
Med Clin (Barc); 2016 Apr; 146 Suppl 1():2-6. PubMed ID: 27426241
[TBL] [Abstract][Full Text] [Related]
48. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
Dikopf A; Wood K; Salgia R
Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
[TBL] [Abstract][Full Text] [Related]
49. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
50. Emerging treatment for ALK-positive lung cancer.
Sharma J; Pareek V; Liu H; Cheng H
Expert Opin Emerg Drugs; 2016 Jun; 21(2):147-55. PubMed ID: 27122312
[TBL] [Abstract][Full Text] [Related]
51. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Russo A; Franchina T; Ricciardi GR; Picone A; Ferraro G; Zanghì M; Toscano G; Giordano A; Adamo V
Oncotarget; 2015 Sep; 6(29):26814-25. PubMed ID: 26308162
[TBL] [Abstract][Full Text] [Related]
52. Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations.
Kuykendall A; Chiappori A
Cancer Control; 2014 Jan; 21(1):67-73. PubMed ID: 24357744
[TBL] [Abstract][Full Text] [Related]
53. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
[TBL] [Abstract][Full Text] [Related]
54. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC; Riely GJ
JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
[TBL] [Abstract][Full Text] [Related]
55. Emerging targeted therapies in non-small cell lung cancer.
Khanal N; Ganti AK
Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
[TBL] [Abstract][Full Text] [Related]
56. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
57. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
58. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
59. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
60. New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).
Russo A; Lopes AR; McCusker MG; Garrigues SG; Ricciardi GR; Arensmeyer KE; Scilla KA; Mehra R; Rolfo C
Curr Oncol Rep; 2020 Apr; 22(5):48. PubMed ID: 32296961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
